Early, Limited and Extensive Stage Management of Small Cell Lung Cancer (SCLC)

Authored by Chinmay Jani, published on 2026-09-02 19:49:50.0

The algorithm is broadly aligned with contemporary SCLC practice for staging (PET/CT and brain MRI), curative-intent limited-stage management with concurrent chemoradiation, and first-line extensive-stage chemoimmunotherapy with PD-L1 blockade. The inclusion of consolidation durvalumab after chemoradiation for limited-stage SCLC reflects emerging/now practice-changing evidence (ADRIATIC) but exact adoption details may vary by guideline update cycle and regulatory status by jurisdiction. Several nodes are under-specified (radiation details, surveillance intervals, and later-line sequencing), and one node appears internally inconsistent regarding maintenance immunotherapy choices.

  1. All Patients Get Systemic Rx
  2. SCLC Workup
    PET/CT MRI Brain NGS
    • Limited Stage
      • Carbo/Etoposide + Radiation (Concurrent, Cycles 2–4)
        • If Responding
          • Durvalumab x 24 Months (ADRIATIC)
            • PCI ± MRI surveillance (case by case basis)
    • Extensive Stage
      • Carbo + Etop + Atezolizumab
        • Brain MRI q2 months if CNS metastases were present and treated with radiation before initiation of systemic therapy
          • Maintenance Atezolizumab* or Durvalumab
            *Maintenance atezolizumab + lurbinectedin => eligible for patients after 4 induction cycles if ≥ stable disease, ECOG PS 0–1, and no history of brain metastases.
            • Progression
              • Tarlatamab (DeLLphi-304)
                • Further progress?
                  • Other chemo therapies
                    Topotecan is an established subsequent-line standard supported by randomized evidence and guideline endorsement; irinotecan is used in some subsequent-line contexts but is less uniformly guideline-preferred than topotecan or lurbinectedin. The node would be more complete if it included lurbinectedin as a common guideline-preferred option in many regions.
    • Very Early Stage (T1–T2, N0, M0)
      • Surgery / SABR
        • Carbo-Etop x4
          • MRI surveillance
  3. Brain Mets?
    • Symptomatic
      • Steroids
        • Radiation
    • Asymptomatic
      • Carboplatin + Etoposide + Atezolizumab with brain MRI q2 months
        • q2 – MRI
tosprivacy